VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CRLCharles River Laboratories International, Inc.
$215.75$10.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCRLCash Flow

Charles River Laboratories International, Inc. (CRL) Cash Flow Statement

28Y historyFree accessUpdated daily

Free cash flow generation has deteriorated, swinging from a 21.1% margin in 2024Q3 to a negative 1.5% in 2026Q1, exacerbated by a $106.1 million working capital outflow.

CRL Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98
Cash from Operations607.03M737.65M734.58M683.9M619.64M760.8M546.58M480.94M441.14M316.26M298.32M286.36M251.05M207.14M207.9M205.28M169.01M225.04M279.95M284.25M164.37M236.7M184.83M123.77M133.66M71.3M33.77M37.57M37.38M
Operating CF Margin %-18.37%18.14%16.56%15.58%21.49%18.69%18.35%19.47%17.03%17.74%21%19.35%17.77%18.41%17.97%14.91%18.71%20.84%23.1%15.53%21.09%24.1%20.17%24.1%15.31%11.01%17.13%19.34%
Operating CF Growth %-92.87%0.42%7.41%10.37%-18.55%39.19%13.65%9.02%39.48%6.02%4.18%14.06%21.2%-0.37%1.27%21.46%-24.9%-19.61%-1.51%72.93%-30.56%28.07%49.34%-7.4%87.47%111.14%-10.12%0.5%-
Net Income-184.65M-142.16M25.29M480.37M492.61M398.84M365.31M254.06M227.22M125.59M156.09M152.04M129.92M105.42M102.12M115.52M-334.11M109.38M-522.27M154.41M-55.78M142M89.79M80.15M50.13M35.41M17.88M17.12M23.38M
Depreciation & Amortization350.1M403.31M361.74M314.12M303.87M265.54M234.92M198.09M161.78M131.16M126.66M94.88M96.44M96.64M81.28M85.23M93.65M93.55M91.18M88.92M85.13M104.64M48.18M31.12M25.73M28.58M18.87M15.64M10.89M
Stock-Based Compensation62.7M71.08M69.89M72.05M73.62M71.47M56.34M57.27M47.35M44M43.64M40.12M31.04M24.54M21.86M21.71M25.53M23.81M24.33M021.09M16.97M3.81M01M4.47M000
Deferred Taxes-85.67M-75.29M-67.43M-50.9M-35.88M-24.01M-133K-21.89M-9.7M28.25M1.95M2.69M7.06M-846K1.31M-8.67M-42.34M15.79M12.67M-9.79M4.04M-37.41M9.08M8.89M11.26M17.19M-887K8.63M-3.13M
Other Non-Cash Items556.29M466.63M375.41M-29.36M-62.02M6.01M-83.59M-12.78M-315K-18.68M6K-12.99M-9.64M6.75M27.38M18.51M418.73M25.95M706.23M10.41M168.52M21M21.77M8.46M28.87M6.59M-1.02M-902K-1.16M
Working Capital Changes-93.28M14.08M-30.33M-102.38M-152.55M42.94M-26.27M6.18M14.81M5.94M-30.02M9.62M-3.77M-25.36M-26.04M-27.01M7.56M-43.45M-32.2M19.21M-58.62M-10.5M12.2M-4.86M16.67M-20.93M-9.31M-2.92M7.39M
Change in Receivables-229K35.74M21.61M-33.43M-150.57M-26.63M-85.63M-8.32M-21.2M-48.28M-52.78M-16.96M-28.09M-19.49M-16.27M7.67M-5.64M21.77M-8.53M-18.96M-18.96M-9.48M-7.26M011.74M-27.5M000
Change in Inventory-891K-48.78M16.8M-62.3M-78.52M-25.16M-18.38M-21.4M-13.34M-17.84M-4.02M3.36M-2.96M-1.57M785K3.77M1.99M-4.38M-9.67M-12.99M-6.47M-5.8M-6.36M-5.73M-1.65M-3.76M-2.34M133K-1.25M
Change in Payables-1.93M2.87M-14.27M-20.43M-2.65M44.9M748K29.77M-12.73M34K22.08M1.17M4.6M-7.08M-3.26M2.21M71K-11.49M8.18M-2.59M-2.59M2.54M-2.32M0-3.75M312K000
Cash from Investing-552.55M-209.32M-245.09M-563.15M-607.92M-1.44B-601.54M-681.5M-955M-72.59M-686.37M-320.29M-297.99M-74.05M-54.99M-36.65M5.76M-208.82M-227.18M-200.78M-107.99M-113.99M-599.97M-63.39M-78.89M-91.92M-14.58M-34.17M-23.03M
Capital Expenditures-215.74M-219.15M-232.97M-318.53M-324.73M-228.77M-166.56M-140.51M-140.05M-82.43M-55.29M-63.25M-56.92M-39.15M-47.53M-49.14M-42.86M-80.01M-197.08M-227.04M-181.75M-95.55M-45.34M-32.7M-37.54M-36.66M-15.56M-12.95M-11.91M
CapEx % of Revenue5.36%5.46%5.75%7.71%8.17%6.46%5.7%5.36%6.18%4.44%3.29%4.64%4.39%3.36%4.21%4.3%3.78%6.65%14.67%18.45%17.17%8.51%5.91%5.33%6.77%7.87%5.08%5.91%6.16%
Acquisitions-403.31M0-5.48M-194.78M-120.12M-1.17B-418.63M-515.7M-824.87M47.45M-648.48M-247.65M-234.27M-29.22M-16.86M02.81M-83.35M-69.15M-11.58M-30.86M-3.4M-571.99M-10.84M-42.5M-55.27M-6.01M-23.05M-11.8M
Investments-----------------------------
Other Investing79.34M20.8M4.55M-2.29M-9.35M264K-1.06M-3.89M-805K-516K3.69M-2.22M-1.15M307K2.79M5.45M950K4.03M51K2.7M189.54M132K1.43M872K1.16M-250K7M1.83M681K
Cash from Financing-83.68M-536.73M-550.93M-85.52M-42.4M672.6M47.25M231.94M558.06M-208.48M390.73M4.55M61.41M-84.24M-111.12M-271.79M-167.9M-80.98M-17.32M-46.43M5.39M-197.58M436.95M-8.79M5.17M47.23M782K-11.5M-8.02M
Debt Issued (Net)168.06M-121.78M-412.19M-75.32M19.79M669.98M30.59M233.87M554.02M-135.58M388.03M75.18M104.38M-11.5M-66.23M-2.26M197.84M-36.13M65.46M-64.55M269.46M-203.6M412.5M-10.08M1.03M-71.57M-202.96M337.53M-1.1M
Equity Issued (Net)-213.89M-359.96M-119.17M-24.16M-38.65M-40.71M-23.98M-18.09M-13.85M-106.91M10.93M-78.11M-122.02M-165.93M-64.19M-283.8M-356.53M-45.9M-115.06M12.36M-161.63M9.13M26.55M3.98M5.27M116.69M235.96M102.99M0
Dividends Paid00000000000000000000-1.92M-1.4M-2.11M-1.9M-1.47M-729K000
Share Repurchases-215.83M-360.67M-119.17M-24.16M-38.65M-40.71M-23.98M-18.09M-13.85M-106.91M-12.27M-117.48M-122.02M-165.93M-64.19M-283.8M-356.53M-45.9M-115.06M-41.62M-249.96M-18M0000000
Other Financing-37.84M-54.98M-19.56M13.96M-23.54M43.32M40.64M16.15M17.88M34.01M-8.23M7.48M79.05M93.19M19.3M14.27M-9.21M1.05M32.28M5.76M-102.25M457K0-783K341K2.84M-32.23M-452.02M-6.92M
Net Change in Cash-33.54M10.43M-78.91M43.27M-5.1M13.2M-6.93M42.73M30.99M46.44M-321K-42.08M4.1M46.24M40.78M-110.25M-3.41M-61.02M18.14M50.07M60.56M-92.75M25.23M59.82M64.24M25.14M18.12M-9.8M6.9M
Free Cash Flow391.29M518.49M501.61M365.37M294.91M532.03M380.01M340.42M301.09M233.83M243.03M223.11M194.13M167.99M160.37M156.14M126.15M145.03M82.87M57.21M-17.38M141.15M139.49M91.06M96.12M34.64M18.2M24.62M25.47M
FCF Margin %9.72%12.91%12.39%8.85%7.42%15.03%13%12.99%13.29%12.59%14.45%16.37%14.96%14.41%14.2%13.66%11.13%12.06%6.17%4.65%-1.64%12.58%18.19%14.84%17.33%7.44%5.94%11.23%13.18%
FCF Growth %-30.53%3.37%37.29%23.89%-44.57%40%11.63%13.06%28.76%-3.78%8.93%14.93%15.56%4.75%2.71%23.77%-13.02%75.02%44.84%429.24%-112.31%1.19%53.18%-5.26%177.46%90.31%-26.06%-3.35%-
FCF per Share7.9910.469.727.105.7510.357.516.856.144.815.074.684.083.463.313.042.022.211.230.83-0.251.952.491.862.030.780.571.242.48
FCF Conversion (FCF/Net Income)-2.12x-5.11x71.34x1.44x1.27x1.95x1.50x1.91x1.95x2.56x1.93x1.92x1.98x2.01x2.14x1.87x-0.50x1.97x-0.54x1.84x-2.95x1.67x2.06x1.54x2.67x2.01x-3.01x2.19x1.60x
Interest Paid26.03M0123.45M132.1M100.75M70.78M72.46M67.81M47.54M27.42M22.76M11.1M10.2M12.03M15.14M22.32M16.14M14.17M14.19M20.11M000000000
Taxes Paid56.66M0126.06M90.37M75.91M75.44M60.06M54.06M67.6M60.38M42.87M24.44M29.7M19.14M17.03M29.12M22.07M27.18M43.16M38.45M000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowDeteriorating
Top Statement Risk

Biotech funding cycle sensitivity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality and Cash Divergence

As evidenced by the most recent quarterly data, CRL's operating cash flow to net income ratio reached a volatile -2.77, highlighting a significant disconnect between accounting profitability and the actual cash-generative capacity of the firm's core preclinical research operations during periods of heavy impairment.

The persistent gap between net income and operating cash flow suggests that reported earnings are heavily influenced by non-cash charges, likely related to goodwill or asset write-downs. Investors should interpret this divergence as a signal that headline earnings may not accurately reflect the underlying cash-generating potential of the business.

Free Cash Flow Margin Volatility

Based on reported financial statements, CRL's free cash flow margin has fluctuated wildly, swinging from a peak of 21.1% in 2024Q3 to a negative 1.5% in 2026Q1, indicating that the company's ability to convert revenue into discretionary cash is highly sensitive to operational disruptions.

This volatility suggests that the company's cost structure is not sufficiently flexible to maintain cash flow stability during revenue downturns. The inability to sustain positive free cash flow in recent periods warrants further investigation into whether this is a temporary cyclical issue or a structural shift in capital intensity.

Capital Intensity and Asset Maintenance

According to historical data, CRL's capital expenditure as a percentage of revenue has averaged roughly 5.5% over the last ten quarters, reflecting the ongoing necessity of maintaining a global vivarium network and specialized laboratory infrastructure to support its preclinical service offerings.

The consistent level of capital spending suggests that a significant portion of cash is committed to maintenance rather than growth, limiting the company's flexibility. Analysts should monitor whether these expenditures are effectively replacing aging assets or if they represent an increasing burden on the company's cash flow profile.

Working Capital Efficiency and Liquidity

As reported in recent filings, working capital changes have been highly erratic, with a notable $106.1 million outflow in 2026Q1, which appears to have significantly pressured the company's liquidity position and overall cash flow generation during the most recent reporting period.

These swings in working capital suggest potential inefficiencies in inventory management or delays in client collections, which are critical for a project-based business model. Investors should monitor whether these fluctuations are indicative of broader operational challenges in managing the supply chain for research models.

Capital Allocation and Inorganic Growth

Based on the provided cash flow data, CRL has prioritized aggressive capital deployment through acquisitions and share repurchases, including a $405.0 million net acquisition spend in 2026Q1, despite the company's recent struggles to maintain positive net income and consistent free cash flow.

This strategy appears to favor inorganic expansion over organic deleveraging, which may increase the company's risk profile in a high-interest-rate environment. The reliance on acquisitions to drive growth warrants further investigation into the return on invested capital for these recent, potentially expensive, strategic moves.

CRL — Frequently Asked Questions

Quick answers to the most common questions about buying CRL stock.

How much cash does Charles River Laboratories International, Inc. (CRL) generate from operations?

Charles River Laboratories International, Inc. (CRL) generated $737.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Charles River Laboratories International, Inc.'s free cash flow?

Charles River Laboratories International, Inc. (CRL) generated $518.5M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Charles River Laboratories International, Inc.'s capital expenditure (CapEx)?

Charles River Laboratories International, Inc. (CRL) spent $219.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Charles River Laboratories International, Inc. distribute cash to shareholders?

In 2025, Charles River Laboratories International, Inc. (CRL) spent $360.7M on share repurchases. This shows the company's commitment to returning capital to its equity investors.